Stay updated with breaking news from Pardeep Jhund. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dapagliflozin reduces the risks of death and cardiovascular events in patients with heart failure regardless of ejection fraction, according to late-breaking research presented in a Hot Line session today at ESC Congress 2022.
By Natalie Grover LONDON (Reuters) - AstraZeneca's blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalisation and ...
Dapagliflozin reduces the risks of death and cardiovascular events in patients with heart failure regardless of ejection fraction, according to late b....
By Natalie Grover LONDON (Reuters) - AstraZeneca's blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalisation and ...
SGLT2 inhibitor shines in landmark DELIVER trial